Novel Target for ALS Treatment Identified

by Sheela Philomena on  August 7, 2012 at 11:27 AM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

An inflammatory monocyte population serves as a potential therapeutic target for amyotrophic lateral sclerosis (ALS).
 Novel Target for ALS Treatment Identified
Novel Target for ALS Treatment Identified

Although the mechanism of ALS is not completely understood, inflammation is believed to play a role in the disease process. A recent study by Howard Weiner and colleagues at Harvard Medical School and Tufts School of Medicine investigated the role of inflammation in a mouse model of ALS. Weiner and colleagues found that the recruitment of activated immune cells known as monocytes into the spinal cord correlated with increased CNS cell death, and this recruitment was mediated by high expression of the chemoattractant protein CCL2 by resident spinal cord-derived immune cells.

Antibody-mediated depletion of the monocyte population reduced cellular recruitment to the spinal cord, decreased CNS cell death, and extended survival time in the mice. The analogous monocyte population in humans with ALS exhibited a similar inflammatory signature to the ALS model mice, suggesting that this cell population could serve as a marker of disease progression in human ALS patients.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Amyotrophic Lateral Sclerosis (ALS) 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...